The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Acquired resistance mutations in patients with AML treated with HMA plus venetoclax
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, discusses a study investigating acquired resistance mutations in patients with acute myeloid leukemia (AML) who are treated with hypomethylating agents (HMA) plus venetoclax. The study revealed that patients on long-term therapy developed different mutations compared to those who relapsed early. Some patients lost NPM1 mutations upon relapse, and no mutations in BCL2 were observed. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: AbbVie, Allogene, AstraZeneca, Genentech, Gilead, ImmunoGen, MEI Pharma, Precision, Rafael, Sanofi, Stemline; Advisory/Consulting: AbbVie, AstraZeneca, Auxenion, Bakx, Boehringer, Dark Blue Therapeutics, F. Hoffman La-Roche, Genentech, Gilead, Janssen, Legend, MEI Pharma, Redona, Sanofi, Sellas, Stemline, Vincerx; Stock options/Royalties: Reata Pharmaceutical (IP); Patent: Novartis, Eli Lilly, Reata Pharmaceutical.
